concept

DOPAMINE

Entity Detail — Knowledge Graph Node

Understanding Entity Pages

This page aggregates everything SciDEX knows about DOPAMINE: its mechanistic relationships (Knowledge Graph edges), hypotheses targeting it, analyses mentioning it, and supporting scientific papers. The interactive graph below shows its immediate neighbors. All content is AI-synthesized from peer-reviewed literature.

470Connections

4Hypotheses

2Analyses

50Outgoing

50Incoming

No summary available yet. View on Wiki →

💡 Concept Info

Name	DOPAMINE
Key Genes/Proteins	IL-6, BDNF, TNF, LRRK2, AMYLOID, ALPHA-SYNUCLEIN
Related Diseases	PARKINSON'S DISEASE, ALZHEIMER'S DISEASE, NEUROINFLAMMATION
Linked Hypotheses	6 hypotheses

Wiki Pages (20)

Knowledge base pages for this entity

cbs-psp-daily-action-plan

therapeutic · 30834 words

→

Personalized Treatment Plan — Atypical Parkinsonism (CBS/PSP)

therapeutic · 15794 words

→

AAV Gene Therapy for Neurodevelopmental Epilepsy — Competitive Landscape & Delivery Alternatives

therapeutic · 15567 words

→

Clinical Management Guide for CBS/PSP

therapeutic · 15224 words

→

Progressive Supranuclear Palsy (PSP)

disease · 12907 words

→

Pathway Diagram

graph TD
    DOPAMINE["DOPAMINE"]
    DOPAMINE -->|"involved_in"| Parkinson_s_Disease["Parkinson's Disease"]
    DOPAMINE -->|"regulates"| neuronal_uptake["neuronal uptake"]
    DOPAMINE -->|"interacts"| GDNF["GDNF"]
    DOPAMINE -->|"interacts"| Substantia_Nigra["Substantia Nigra"]
    DOPAMINE -->|"treats"| diabetic_retinal_neurodegenera["diabetic retinal neurodegeneration"]
    DOPAMINE -->|"activates"| NRF2["NRF2"]
    DOPAMINE -->|"regulates"| GPX4["GPX4"]
    DOPAMINE -->|"regulates"| BDNF["BDNF"]
    DOPAMINE -->|"expressed in"| striatum["striatum"]
    COMT["COMT"] -->|"degrades"| DOPAMINE
    Atremorine["Atremorine"] -->|"interacts"| DOPAMINE
    GDNF -->|"inhibits"| DOPAMINE
    Substantia_Nigra -->|"interacts"| DOPAMINE
    levodopa["levodopa"] -->|"converts_to"| DOPAMINE

Outgoing (114)

Target	Relation	Type	Str
ALPHA-SYNUCLEIN	activates	protein	0.70
NEUROINFLAMMATION	treats	phenotype	0.70
ALZHEIMER'S DISEASE	regulates	disease	0.70
DOPAMINERGIC NEURONS	targets	cell_type	0.65
DEPRESSION	treats	disease	0.65
BDNF	causes	gene	0.65
PARKINSON'S DISEASE	targets	disease	0.65
NEURONS	produces	cell_type	0.65
NEURODEGENERATION	protects_against	phenotype	0.65
LYSOSOMAL DYSFUNCTION	regulates	phenotype	0.65
LYSOSOMAL DYSFUNCTION	causes	phenotype	0.65
GABA	inhibits	phenotype	0.65
TAU	treats	protein	0.65
TH	produces	gene	0.65
TH	targets	gene	0.65
CORTEX	causes	brain_region	0.65
LIPID PEROXIDATION	causes	phenotype	0.65
AUTOPHAGY	regulates	phenotype	0.65
AUTOPHAGY	degrades	phenotype	0.65
NRF2	regulates	gene	0.65
LEVODOPA	activates	drug	0.65
PARKINSON'S DISEASE	implicated_in	disease	0.60
SUBSTANTIA NIGRA	exacerbates	brain_region	0.60
PARKINSON'S DISEASE	biomarker_for	disease	0.60
GABA	implicated_in	phenotype	0.55
NEURODEGENERATION	implicated_in	phenotype	0.55
PARKIN	expressed_in	gene	0.55
STRIATUM	implicated_in	brain_region	0.55
SUBSTANTIA NIGRA	expressed_in	brain_region	0.55
GABA	participates_in	phenotype	0.55
NEUROGENESIS	implicated_in	phenotype	0.55
α-SYNUCLEIN	associated_with	concept	0.50
α-SYNUCLEIN	causes	concept	0.50
α-SYNUCLEIN	activates	concept	0.50
α-SYNUCLEIN	inhibits	concept	0.50
α-SYNUCLEIN	regulates	concept	0.50
Neuroprotection	protects_against	process	0.50
DOPAMINERGIC NEURONS	protects_against	concept	0.50
Proteins	activates	protein	0.50
DOPAMINERGIC NEURONS	interacts_with	concept	0.50
FRONTAL	associated_with	concept	0.50
PREFRONTAL CORTEX	regulates	concept	0.50
SEROTONIN	activates	concept	0.50
SEROTONIN	associated_with	concept	0.50
SEROTONIN	regulates	concept	0.50
DOPAMINERGIC NEURONS	inhibits	concept	0.50
EXTRACELLULAR VESICLES	activates	concept	0.50
DOPAMINERGIC NEURONS	associated_with	concept	0.50
DOPAMINERGIC NEURONS	activates	concept	0.50
CENTRAL NERVOUS SYSTEM	associated_with	concept	0.50

Incoming (356)

Source	Relation	Type	Str
PARKINSON'S DISEASE	associated_with	disease	1.00
ALZHEIMER'S DISEASE	associated_with	disease	1.00
IL-6	associated_with	gene	0.90
BDNF	associated_with	gene	0.90
TNF	associated_with	gene	0.82
LRRK2	associated_with	gene	0.74
AMYLOID	associated_with	protein	0.74
ASTROCYTE	protects_against	cell_type	0.70
TH	activates	gene	0.70
DRD2	causes	gene	0.70
PARKINSON'S DISEASE	destabilizes	disease	0.70
ALPHA-SYNUCLEIN	interacts_with	protein	0.70
ALPHA-SYNUCLEIN	causes	protein	0.70
ALPHA-SYNUCLEIN	inhibits	protein	0.70
TH	regulates	gene	0.70
PARKINSON'S DISEASE	exacerbates	disease	0.70
OXIDATIVE STRESS	interacts_with	phenotype	0.70
CHOLESTEROL	inhibits	phenotype	0.70
PARKIN	causes	gene	0.70
PARKIN	associated_with	gene	0.66
LC3	associated_with	protein	0.66
ROS	activates	phenotype	0.65
MTOR	treats	gene	0.65
NEUROBLASTOMA	inhibits	disease	0.65
TH	inhibits	gene	0.65
TNF	inhibits	gene	0.65
MODAFINIL	interacts_with	drug	0.65
SUCCINATE	inhibits	phenotype	0.65
L-DOPA	inhibits	drug	0.65
TH	interacts_with	gene	0.65
TH	causes	gene	0.65
METFORMIN	causes	drug	0.65
NEURODEGENERATION	treats	phenotype	0.65
TAU	inhibits	protein	0.65
CANAGLIFLOZIN	activates	drug	0.65
SCHIZOPHRENIA	regulates	disease	0.65
TH	biomarker_for	gene	0.65
PARKINSON'S DISEASE	treats	disease	0.65
MICROGLIA	regulates	cell_type	0.65
MICROGLIA	causes	cell_type	0.65
PARKINSON'S DISEASE	phosphorylates	disease	0.65
INFLAMMATION	treats	phenotype	0.65
PARP1	treats	gene	0.65
SUPEROXIDE	activates	phenotype	0.65
TAU	protects_against	protein	0.65
PARKINSON'S DISEASE	causes	disease	0.65
LOCUS COERULEUS	produces	brain_region	0.65
LOCUS COERULEUS	causes	brain_region	0.65
TFEB	protects_against	gene	0.65
NEURON	treats	cell_type	0.65

Targeting Hypotheses (4)

Hypotheses where this entity is a therapeutic target

Hypothesis	Score	Disease	Analysis
Dopaminergic Ventral Tegmental-Hippocampal Circuit Protectio	0.494	neuroscience	Circuit-level neural dynamics in neurode
Correcting Gut Microbial Dopamine Imbalance to Support Syste	0.412	neurodegeneration	What are the mechanisms by which gut mic
BH4 Cofactor Restoration as Primary Driver of >500-Fold Dopa	0.396	neurodegeneration	What molecular mechanisms underlie Atrem
Bacterial Enzyme-Mediated Dopamine Precursor Synthesis	0.364	neurodegeneration	What are the mechanisms by which gut mic

Mentioning Analyses (2)

Scientific analyses that reference this entity

How does PSEN2 mechanistically regulate α-synuclein expression and pathology in

neurodegeneration | 2026-04-13 | 0 hypotheses

What molecular mechanisms underlie Atremorine's dramatic dopamine enhancement in

neurodegeneration | 2026-04-13 | 2 hypotheses Top: 0.467

Related Papers (20)

Scientific publications cited in analyses involving this entity

Title & PMID	Authors	Journal	Year
Gene therapy for Parkinson's disease: current landscape, translational challenge [PMID:41837837]	Evola V, Parmar MS	Expert review of neurotherapeu	2026
Striatal Dysregulation of Angpt2 and Circadian Gene Expression in a Rotenone Rat [PMID:41925987]	Al Saeedy DY, Hawkins E, Dozmorov MG, Tr	J Mol Neurosci	2026
A quantitative DOPA decarboxylase biomarker for diagnosis in Lewy body disorders [PMID:41699128]	["Bolsewig K", "Bellomo G", "Hok-A-Hin Y	Nature medicine	2026
Plasma pTau 217/β-amyloid 1-42 ratio for enhanced accuracy and reduced uncertain [PMID:41562409]	Benina N, Buitrago L, De Simone FI, Radw	Brain	2026
Increased plasma DOPA decarboxylase levels in Lewy body disorders are driven by [PMID:39881147]	["Bolsewig K", "Willemse E", "S\u00e1nch	Nature communications	2025
Neurosurgical gene therapy for central nervous system diseases. [PMID:39191071]	Patel RV, Nanda P, Richardson RM	Neurotherapeutics : the journa	2024
Characterization of Vps13b-mutant mice reveals neuroanatomical and behavioral ph [PMID:37573958]	["Montillot C", "Skutunova E", "Ayushma"	Neurobiology of disease	2023
Interplay between the catecholaminergic enzymatic axis and neurodegeneration/neu [PMID:36692274]	["Motta C", "Assogna M", "Bonomi C", "Di	European journal of neurology	2023
Long-term efficacy and safety of eladocagene exuparvovec in patients with AADC d [PMID:34763085]	Tai CH, Lee NC, Chien YH, Byrne BJ, Mura	Molecular therapy : the journa	2022
Gene therapy restores dopamine transporter expression and ameliorates pathology [PMID:34011628]	Ng J, Barral S, De La Fuente Barrigon C,	Science translational medicine	2021
Current Clinical Applications of In Vivo Gene Therapy with AAVs. [PMID:33309881]	Mendell JR, Al-Zaidy SA, Rodino-Klapac L	Molecular therapy : the journa	2021
Targeting autophagy using small-molecule compounds to improve potential therapy [PMID:34729301]	Zhang K, Zhu S, Li J, Jiang T, Feng L, P	Acta pharmaceutica Sinica. B	2021
Bi-allelic loss of function variants in SLC30A5 as cause of perinatal lethal car [PMID:33547425]	Lieberwirth JK, Joset P, Heinze A, Hents	European journal of human gene	2021
Graphene bilayers with a twist. [PMID:33208935]	["Andrei E", "MacDonald A"]	Nature materials	2020
Reconstruction of cell spatial organization from single-cell RNA sequencing data [PMID:32541867]	["Ren X", "Zhong G", "Zhang Q", "Zhang L	Cell research	2020
Gene therapy for neurodegenerative disorders: advances, insights and prospects. [PMID:32963936]	Chen W, Hu Y, Ju D	Acta pharmaceutica Sinica. B	2020
Environmental Regulation, Technological Innovation, and Export Competitiveness: [PMID:32102174]	Liu J, Xie J	International journal of envir	2020
Predicting Subjective Recovery from Lower Limb Surgery Using Consumer Wearables. [PMID:33442582]	Karas M, Marinsek N, Goldhahn J, Foschin	Digital biomarkers	2020
Ligand entry in human ileal bile acid-binding protein is mediated by histidine p [PMID:30886237]	["Horv\u00e1th G", "Egyed O", "Tang C",	Scientific reports	2019
[Skin Changes in POEMS Syndrome]. [PMID:30988219]	["Kuwabara S"]	Brain and nerve = Shinkei kenk	2019

DOPAMINE

Understanding Entity Pages

Wiki Pages (20)

cbs-psp-daily-action-plan

Personalized Treatment Plan — Atypical Parkinsonism (CBS/PSP)

AAV Gene Therapy for Neurodevelopmental Epilepsy — Competitive Landscape & Delivery Alternatives

Clinical Management Guide for CBS/PSP

Progressive Supranuclear Palsy (PSP)

Corticobasal Syndrome (CBS)

Novel Therapy Index

Parkinson's Disease

Atypical Parkinsonism

Device Therapies Comparison for CBS/PSP

Section 148: Advanced Nutritional Biochemistry in CBS/PSP

Alpha-Synuclein Pathology

PD Combination Therapy Matrix

Corticobasal Degeneration (CBD)

Therapeutics

Section 162: Advanced Antioxidant and Redox Therapy in CBS/PSP

Neurons — Cell Type Hierarchy

Frontotemporal Dementia (FTD) Mechanistic Pathway

NRF2 Oxidative Stress Pathway

Multiple System Atrophy